|
|
Feline eosinophilic granuloma complex (EGC)
© Tricia A. Starnes, DVM; Kenneth S. Latimer, DVM, PhD; Pauline M. Rakich, DVM, PhD; Perry J. Bain, DVM, PhD; http://www.vet.uga.edu/vpp/clerk/Starnes/index.htm
Feline eosinophilic granuloma complex (EGC) is a common inflammatory skin disease of cats, which consists of a group of lesions that affect the skin, mucocutaneous junctions, and oral cavity. EGC is not a specific disease but simply several cutaneous reaction patterns in cats. Classically, three lesions have been characterized in feline EGC: (1) the indolent ulcer (rodent ulcer), (2) the eosinophilic plaque, and (3) the eosinophilic granuloma. These lesions are grouped together because they may occur in the same patient and may respond to the same therapy. There are no breed predilections to EGC, but females may be predisposed to development of lesions. Young to middle-age cats usually are affected (average age 3.5 years) and peripheral lymphadenopathy (swollen glands) is often associated with these dermatoses. Long-standing and more extensive EGC is associated with chronic immune stimulation and an ensuing polyclonal gammopathy. The cause of EGC is unknown; however, an underlying hypersensitivity such as a food allergy, atopy, or insect allergy (particularly to fleas and mosquitoes) often has been associated with these lesions. Since antibiotic therapy clears or significantly improves some lesions, bacterial infection also may be implicated. However, the response to antibiotics may be due to the immune-modulating effects of the antibiotic therapy rather than any antibacterial properties. A genetic predisposition to EGC may exist because eosinophilic granulomas and indolent ulcers have been observed in a colony of specific pathogen-free cats and other cats with limited genetic diversity. Also, it has been postulated that EGC may be an autoimmune phenomenon because the presence of circulating antiepithelial autoantibodies has been demonstrated in one study of affected cats. Conversely, due to the severe epidermal injury and dermal reaction in cats with EGC, altered antigens may have been released resulting in production of autoantibody. The main pathogenic events in these lesions are most likely caused by eosinophil recruitment and degranulation. Circulating eosinophils move into tissues (especially into subepithelial sites) in reaction to inflammation prompted by antigen-antibody complexes, parasites, or micro-organisms (Fig. 1). Since eosinophils are attracted to and phagocytize antigen-antibody complexes, the presence of eosinophils in the EGC indicates that it is an immune-mediated disease. Many other diseases may have a similar clinical presentation as EGC. Due to the correlation with hypersensitivity disorders, a diagnostic evaluation for allergic skin disease should be conducted. Diagnostic tests may be comprised of intradermal skin testing, a hypoallergenic food trial, a flea control trial, and avoidance of mosquitoes. These tests are most commonly performed when EGC is non-responsive to glucocorticoid therapy. Other differential diagnoses to consider are infectious ulcers or granulomas (bacterial, fungal, FeLV-associated) and trauma. In addition, the clinical appearance of several tumours (squamous cell carcinoma, mast cell tumour, lymphoma, fibrosarcoma, and mammary carcinoma) may be similar to granulomas. Cytology and/or biopsy specimens are recommended to exclude neoplasia when any cutaneous mass is evaluated.
Dermatohistopathology
Biopsy is nondiagnostic and reveals a hyperplastic, ulcerated, superficial perivascular to interstitial dermatitis (typically with a preponderance of neutrophils and mononuclear cells) and
fibrosis. Biopsy is primarily used to exclude malignancy. Eosinophilia rarely is observed in the
blood.
Eosinophils are observed commonly on cytologic imprints, but neutrophils and bacteria may prevail if the lesion is secondarily
infected. Biopsy findings are variable and may range from a hyperplastic, superficial and deep, perivascular dermatitis with eosinophilia to interstitial or diffuse eosinophilic
dermatitis. Flame figures may be observed. Diffuse spongiosis may be present in the epidermis.6 Eosinophilia is common in peripheral
blood.
Eosinophils are seen commonly in cytologic imprints, but neutrophils and bacteria may prevail if the granuloma is secondarily infected. Nodular to diffuse granulomatous dermatitis with multifocal areas of flame figure formation are visible in biopsy specimens. Eosinophils, histiocytes, and multinucleated giant cells with foci of collagen degeneration4 are typical (Fig. 6). Mast cell hyperplasia may be observed occasionally, especially with the application of metachromatic stains (e.g., Giemsa or toluidine blue stains, Fig. 7) Dermal foci of amorphous to granular, eosinophilic to partly basophilic debris are described as being characteristic histopathological traits of eosinophilic granulomas. In chronic lesions, eosinophils are not as prevalent.6 Eosinophilia may occur in the blood (especially with oral lesions).
Treatment Identification and treatment of any suspected underlying disease should be performed when managing the various forms of feline EGC. Immunosuppressive therapy is the most common treatment and systemic glucocorticoids are often effective. Cats have fewer steroid receptors on their cells and thus require higher doses of glucocorticoids than most other species. Prednisone or prednisolone may be given orally (4.4 mg/kg every 24 hours) until the lesions are healed. Alternatively, injections of methylprednisolone acetate (20 mg/cat subcutaneously every 2 -3 weeks until lesions resolve), or oral administration of glucocorticoids (dexamethasone at 0.4 mg/kg every 24 hours or triamcinolone at 0.8mg/kg every 24 hours) may be effective. Recurrent lesions may be managed with oral glucocorticoids given every other day or repeated subcutaneous injections of methylprednisolone (which should never be given more frequently than every 2 months). Considerable improvement of the lesions should be evident within 2-4 weeks.4 When the lesions have improved, glucocorticoid therapy should be gradually tapered to the lowest possible dosage. Omega-3/omega-6 fatty acid containing products have been shown to be useful in some cats and reduce glucocorticoid requirements in others. For lesions that are not responsive to steroid therapy, immunomodulation may be considered as an alternative therapy. Some cats respond to systemic antibiotics given for 2-3 weeks. Other immunomodulating drugs include chlorambucil, levamisole, thiabendazole, and alpha-interferon. However, some studies indicate that alpha-interferon is not as useful in treatment of eosinophilic plaques and granulomas. Other modes of treatment that occasionally are effective include radiotherapy, cryosurgery, laser therapy, surgical excision, and mixed bacterial vaccines. In addition, unpublished reports demonstrate that occlusive biosynthetic absorbent wound dressing applied to lesions for 48 hours may be beneficial. The lesions exhibit a discernible decrease in pruritus following application. Progestational compounds, such as megestrol acetate, also have been used successfully; however, these drugs are not recommended due to their adverse side effects. Two groups of "alternative" therapies, most of which have been tried in small numbers of cases, only in prospective studies or have been empirically / anecdotally reported as effective, are available.
Prognosis
1. Fondati A, Fondevila D, Ferrer L: Histopathological study of feline eosinophilic dermatoses. Vet Dermatol 6:333-338, 2001. | |||||||||||||||||||||||